The introduction of Wegovy, a {semaglutide-based|GLP-1 target drug, in the British Isles has prompted detailed assessment and the establishment of specific guidelines for its administration. Current national positioning emphasizes that Wegovy is primarily intended for individuals with significant weight concerns, or those with weight-related comorb